Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Product update

Prostap QT prolongation

The summary of product characteristics for Prostap (leuprorelin; Takeda) has been updated to warn that androgen deprivation therapy may prolong the QT interval, therefore patients with a history of QT prolongation, those with risk factors for QT prolongation and patients receiving drugs that might prolong QT interval should be assessed before starting treatment. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067428

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.